NICHOLAS TINDONG: Open Payments
NPI 1386637098 · LANHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,744 in 51 payments from 11 companies in 2025. Trend: 2023 $213 · 2024 $599 · 2025 $1,744
Food & beverage: $1,744
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $344 |
| Otsuka America Pharmaceutical, Inc. | 4 | $279 |
| Alkermes, Inc. | 11 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $196 |
| Neurocrine BioSciences, Inc. | 3 | $191 |
| Axsome Therapeutics, Inc. | 4 | $182 |
| Lundbeck LLC | 7 | $161 |
| Janssen Pharmaceuticals, Inc | 2 | $64 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
Products named: ABILIFY MAINTENA, VRAYLAR, ARISTADA, CAPLYTA, INGREZZA, Auvelity, REXULTI, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
